From The Motley Fool · The Motley Fool Team · · 40s
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
Kiniksa Pharmaceuticals raises 2026 revenue guidance to $1.045B-$1.050B as ARCALYST sales surge.
In brief
Kiniksa Pharmaceuticals raises 2026 revenue guidance to $1.045B-$1.050B as ARCALYST sales surge. Kiniksa Pharmaceuticals increased full-year 2026 revenue guidance to $1.045 billion-$1.050 billion after ARCALYST sales grew 58% year-over-year to $286 million. Originally reported by The Motley Fool.
Q3 2026 Earnings Call
Kiniksa Pharmaceuticals raised full-year 2026 revenue guidance to $1.045 billion-$1.050 billion.
ARCALYST Sales Surpassed Guidance
ARCALYST revenue grew 58% year-over-year to $286 million in Q3 2026.
“ARCALYST revenue grew 58% year-over-year to $286 million in the third quarter”
AI-Targeted Marketing Campaign
Heart's Home campaign increased ARCALYST website traffic 12-fold compared to baseline.
“we've seen a 12-fold increase in the traffic to our ARCALYST website compared to baseline levels”
Pipeline Candidates Target Less Frequent Dosing
KPL-387 and KPL-1161 pipeline candidates target less frequent dosing schedules.
“The pivotal phase III study with KPL-387 continues to enroll and dose patients”
At a glance
Kiniksa Pharmaceuticals increased full-year 2026 revenue guidance to $1.045 billion-$1.050 billion after ARCALYST sales grew 58% year-over-year to $286 million.
